CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
Authors
A Raben
AD Harries
+28 more
C E Wright
C S McArdle
CL Loprinzi
D C McMillan
DC McMillan
DC McMillan
DC McMillan
DC McMillan
DC McMillan
E Schmoll
HR Scott
J Feliu
J Goransson
J Inagaki
JS Falconer
K C H Wigmore
KA Kern
KCH Fearon
L Ovesen
NK Aaronson
NS Tchemedyian
P O’Gorman
S J Wigmore
SB Heymsfield
SJ Wigmore
T Preston
V Mor
WJ Hannan
Publication date
1 January 1999
Publisher
Nature Publishing Group
Doi
Cite
View
on
PubMed
Abstract
The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted. © 1999 Cancer Research Campaig
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Enlighten: Publications
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.gla.ac.uk:60217
Last time updated on 09/04/2020
Enlighten
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.gla.ac.uk:60217
Last time updated on 08/10/2012
Edinburgh Research Explorer
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.ed.ac.uk:publications...
Last time updated on 08/02/2015
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 01/04/2019